From "Supply" to "Co-Creation": SoYoung and Jinbo Rewrite the Upstream-Downstream Relationship in Medical Aesthetics

```

The collaboration model between the upstream and downstream sectors of the medical aesthetics industry chain is quietly changing.

Recently, SoYoung and Jinbo Bio have jointly launched "Miracle Collagen" Weiyimei ColPact, covering full-scenario anti-aging for the face and scalp with recombinant collagen.

ColPact not only continues Weiyimei’s brand system under Jinbo Bio, but is also included in SoYoung’s "GREEN LABEL" product system.

Such "co-branding" is uncommon in previous upstream-downstream cooperation models.

For a long time, the mainstream cooperation patterns in the industry have mainly fallen into two categories:

The first is standard supply, where upstream manufacturers provide mature products that downstream institutions directly purchase and use, with the brand belonging to the upstream supplier;

The second is custom development, where downstream raises the demand and upstream produces according to requirements, but the product is usually named after the institution’s brand.

However, the fact that ColPact bears the marks of both parties this time to some extent means that the relationship between upstream and downstream is moving from a simple supply relationship to co-creation.

Whether co-creation will become mainstream in the future, SoYoung Group Chairman and CEO Jin Xing believes, still depends on the scarcity of the product category.

"There are actually many ways to organize the supply chain, and indeed, for each category you need to look at its own circumstances. You will find that today there are still some categories that are very high-end, for example, recombinant type III collagen is hard to achieve breakthroughs with even in the U.S. For such categories, we work with outstanding major manufacturers." Jin Xing pointed out, "Some products are more universal today—such as hyaluronic acid. In fact, many factories can make it, and the quality can be very good. In this case, another model of cooperation may be chosen. I think we should still take a differentiated approach for each subcategory."

The co-creation model on one hand recognizes the contributions of both parties to the product, and on the other hand, represents a rebalancing of price bargaining between upstream and downstream.

Compared to Jinbo Bio’s original pricing, "Weiyimei" ultra-pure type III humanized collagen (4mg) sells for 1,949 yuan on the SoYoung platform.

Under the traditional OEM logic, SoYoung would naturally want to get a lower price from Jinbo Bio to participate in market competition.

However, the co-branded ColPact product of the same specifications is finally priced at 1,999 yuan, essentially aligning with Weiyimei’s product price.

This also reflects a new kind of "price balance" reached on scarce categories between upstream and downstream: working together to maximize added value.

For the upstream manufacturer Jinbo Bio, allowing the downstream brand to "share the table" and co-brand in turn brings joint protection of the core product’s positioning from the channel partner. Both sides avoid fighting over pricing systems, and instead jointly earn differentiated brand premiums through the addition of technology and services.

Amid a slowdown in market demand in the medical aesthetics industry, whether this kind of co-creation cooperation model can bring more incremental space to upstream and downstream players is attracting attention.

Risk Warning and DisclaimerThe market involves risks, and investment requires caution. This article does not constitute personal investment advice, nor does it take into account the special investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their own situation. Investing accordingly is at your own risk. ```